Assessing the influence of insulin type (ultra-rapid vs rapid insulin) and exercise timing on postprandial exercise-induced hypoglycaemia risk in individuals with type 1 diabetes: a randomised controlled trial
Diabetologia · 2024
DOI: 10.1007/s00125-024-06234-0 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetologia, 2024. Verfasst von Joséphine Molveau und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institut de recherches cliniques de Montréal, Montréal, QC, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Hypoglycemia, Exercise, Postprandial Period. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Novo Nordisk Canada.
Themen: Diabetes mellitus
Abstract (Originalsprache)
AIMS/HYPOTHESIS: The relationship between pre-meal insulin type, exercise timing and the risk of postprandial exercise-induced hypoglycaemia in people living with type 1 diabetes is unknown. We aimed to evaluate the effects of exercise timing (60 vs 120 min post meal) and different insulin types (aspart vs ultra-rapid aspart) on hypoglycaemic risk. METHODS: This was a four-way crossover randomised trial including 40 individuals with type 1 diabetes using multiple daily injections (mean HbA1c 56 mmol/mol [7.4%]). Participants, who were recruited from the Montreal Clinical Research Institute, undertook 60 min cycling sessions (60% of V ˙ O 2 peak ) after breakfast (60 min [EX60min] or 120 min [EX120min] post meal) with 50% of their usual insulin dose (aspart or ultra-rapid aspart). Eligibility criteria included age ≥18 years old, clinical diagnosis of type 1 diabetes for at least 1 year and HbA1c ≤80 mmol/mol (9.5%). Participants were allocated using sequentially numbered, opaque sealed envelopes. Participants were masked to their group assignment, and each participant was allocated a unique identification number to ensure anonymisation. The primary outcome was change in blood glucose levels between exercise onset and nadir. RESULTS: Prior to exercise onset, time spent in hyperglycaemia was lower for EX60min vs EX120min (time >10.0 mmol/l: 56.6% [1.2-100%] vs 78.0% [52.7-97.9%]; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de recherches cliniques de Montréal, Montréal, QC, Canada.
- Département de Nutrition, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada.
- ULR 7369 - URePSSS - Unité de Recherche Pluridisciplinaire Sport Santé Société, Université de Lille, Université d'Artois, Université du Littoral Côte d'Opale, Lille, France.
- Department of Applied Human Sciences, Faculty of Science, University of Prince Edward Island, Charlottetown, PE, Canada.
- Division of Endocrinology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada.
- Institut Universitaire de France (IUF), Paris, France.
Förderung
- Novo Nordisk Canada
Zitieren
APA
Molveau, J., Myette-Côté, É., Tagougui, S., Taleb, N., St-Amand, R., Suppère, C., Bourdeau, V., Heyman, E., & Rabasa-Lhoret, R. (2024). Assessing the influence of insulin type (ultra-rapid vs rapid insulin) and exercise timing on postprandial exercise-induced hypoglycaemia risk in individuals with type 1 diabetes: a randomised controlled trial. Diabetologia. https://doi.org/10.1007/s00125-024-06234-0
Vancouver
Molveau J, Myette-Côté É, Tagougui S, Taleb N, St-Amand R, Suppère C, et al. Assessing the influence of insulin type (ultra-rapid vs rapid insulin) and exercise timing on postprandial exercise-induced hypoglycaemia risk in individuals with type 1 diabetes: a randomised controlled trial. Diabetologia. 2024. doi:10.1007/s00125-024-06234-0
BibTeX
@article{Molveau2024,
author = {Molveau, Joséphine and Myette-Côté, Étienne and Tagougui, Sémah and Taleb, Nadine and St-Amand, Roxane and Suppère, Corinne and Bourdeau, Valérie and Heyman, Elsa and Rabasa-Lhoret, Rémi},
title = {Assessing the influence of insulin type (ultra-rapid vs rapid insulin) and exercise timing on postprandial exercise-induced hypoglycaemia risk in individuals with type 1 diabetes: a randomised controlled trial},
journal = {Diabetologia},
year = {2024},
doi = {10.1007/s00125-024-06234-0}
}
EUVIMED